Industry News
Biotechnology Industry News
Artificial intelligence has long…
Artificial intelligence has long been seen as a way to supercharge drug development. But a whole new frontier of computing is opening up at cutting-edge labs around the globe—and Big Pharmas are getting in on
Pfizer and Valneva have blamed…
Pfizer and Valneva have blamed “fewer than anticipated” Lyme disease cases for the failure of their phase 3 trial to hit its key goal. But the companies still plan to file the vaccine with regulators.
When Ron Cohen, M.D., CEO of Oryon…
When Ron Cohen, M.D., CEO of Oryon Cell Therapies, recently dug into the company’s Parkinson’s disease data, he told Fierce Biotech it “sang” to him. The former internist-turned-biotech CEO knew a thing or two about
Genentech is halting development…
Genentech is halting development of an antibody for two rare genetic diseases after the candidate failed to boost muscle growth, raising questions about whether the molecule can preserve muscle in two still-ongoing obesity trials.
Novartis has struck a deal to buy…
Novartis has struck a deal to buy Synnovation Therapeutics’ pan-mutant‑selective PI3Kα inhibitor for $2 billion upfront, securing an asset that could defend its breast cancer franchise from challengers including Eli Lilly.
Gilead has handed back a next-gen…
Gilead has handed back a next-gen hepatitis B antiviral to Assembly Biosciences, while the two companies continue to partner on other assets.
Renowned cardiologist Eric Topol,…
Renowned cardiologist Eric Topol, M.D., is setting sail with Flagship Pioneering as an academic advisor for the firm’s Preemptive Health and Medicine Initiative. Topol is director of the Scripps Research Translational Institute, which he founded
Genentech has elected to stop a…
Genentech has elected to stop a phase 2 trial of a RIPK1 inhibitor early and dump the asset after an analysis revealed the candidate was unlikely to meet the study’s primary endpoint.
About a month after Pfizer CEO…
About a month after Pfizer CEO Albert Bourla, Ph.D., told investors that the Big Pharma’s pipeline pruning was mostly done, the company has trimmed another branch. Pfizer has scrapped a phase 1 antibody-drug conjugate that
Phage-focused BiomX is undergoing…
Phage-focused BiomX is undergoing a “strategic and financial reset” in efforts to improve the biotech’s financial position, mapping out a possible shift from therapeutics to the defense sector.
Fauna Bio, which signed an…
Fauna Bio, which signed an obesity-focused partnership with Lilly back in 2023, has now unveiled the target that it will be focusing on.
More than 100 marchers took to…
More than 100 marchers took to Capitol Hill on Wednesday after carrying a coffin to the FDA in a symbolic protest highlighting lives they say could be lost to regulatory delays affecting a group of
With the obesity numbers for Eli…
With the obesity numbers for Eli Lilly’s experimental triple agonist retatrutide already stacking up nicely, the company is rounding out its pitch for the drug with new top-line data on its ability to lower blood
For children with Dravet syndrome,…
For children with Dravet syndrome, a rare, severe genetic disease characterized by fever-related seizures and intellectual disability, developmental delays begin after the first few years of normal development. Stoke Therapeutics is developing a drug designed
Proactive coordination is…
Proactive coordination is essential to protect patients, sponsors and trial integrity, especially as teams navigate the new UK Clinical Trial Regulation. Hear why alignment matters more than ever.
Crossbow Therapeutics has…
Crossbow Therapeutics has successfully hit a $77 million series B round, which the biotech will use to fund a trial of its lead T-cell engager (TCE) and fill its quiver with more T-Bolts.
Aspen Neuroscience’s stem cell…
Aspen Neuroscience’s stem cell therapy improved Parkinson’s disease symptoms for all eight treated patients after one year, with the San Diego biotech now planning for a pivotal phase 3 trial later this year.
Health authorities in the U.S. are…
Health authorities in the U.S. are continuing their move away from animal testing in drug development, with the FDA signaling an openness to new approaches that haven’t been validated.
Since raising a mind-boggling $1…
Since raising a mind-boggling $1 billion in 2024, AI-driven Xaira Therapeutics has remained largely silent on where that money is being put to work. Last week, the company’s Chief Operating Officer, Jeff Jonker, opened up
The pharma is transitioning…
The pharma is transitioning operations and management of its New York City JLABS space to the site owner, the New York Genome Center (NYGC).